GeNeuro SA, a clinical-stage biotech company, is navigating challenges in the development of its MS treatment, GNbAC1, amidst a volatile stock price and uncertain financial landscape.

GeNeuro SA navigates financial challenges while advancing its promising clinical developments for autoimmune diseases, including its flagship product GNbAC1 for multiple sclerosis.